Accepted answer
4 weeks is 28 days, and the first question about any marker is whether 28 days is long enough for it to have finished moving. GGT turns over slowly, over two to three weeks, and responds to hepatic fat and to alcohol with roughly equal enthusiasm. Against 28 days the marker is at or near the edge of its own settling time, so part of what you are reading is the transition rather than the destination. The second question is the denominator. Weight loss moves plasma volume, muscle mass and intake at once, and several of the markers on a routine panel are ratios with one of those three underneath them. Repeat before interpreting. A single value 28 days in, with no baseline drawn under the same conditions, is a number rather than a change — and nothing here is medical advice.
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Headline results, principal programmes
| Trial | Agent | n | Duration | Primary result |
|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.
Decide the action for each result before you order the test.